Detalhe da pesquisa
1.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Blood
; 137(20): 2817-2826, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33259589
2.
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy.
Br J Haematol
; 188(3): 404-412, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31468521
3.
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Oncologist
; 24(7): 921-932, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30552157
4.
A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma.
Cancer
; 123(4): 576-582, 2017 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27727447
5.
Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy.
Br J Haematol
; 177(2): 254-262, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28169430
6.
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
J Clin Oncol
; 39(15): 1609-1618, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33683917
7.
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
Blood Adv
; 5(23): 5332-5343, 2021 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34547767
8.
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
Clin Genitourin Cancer
; 18(6): 469-476.e4, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32641261
9.
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
Nat Med
; 24(6): 749-757, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29867230
10.
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
Nat Med
; 24(12): 1941, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30291359
11.
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
J Clin Oncol
; 35(31): 3538-3546, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28862883
12.
A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC).
Target Oncol
; 11(5): 643-653, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27154357
13.
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
J Clin Oncol
; 22(5): 785-94, 2004 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14990633
14.
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.
Blood
; 111(1): 86-93, 2008 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17893227